The Global Alliance For Tb Drug Development - Pharma

Relevant Publications

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.

Issue Release: 2019

Pretomanid: First Approval.

Issue Release: 2019

TB Alliance regimen development for multidrug-resistant tuberculosis.

Issue Release: 2016

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Issue Release: 2015

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Issue Release: 2014

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.

Issue Release: 2013

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

Issue Release: 2013

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Issue Release: 2012

[Developmental status of new antituberculous drugs].

Issue Release: 2011

The TB Alliance: overcoming challenges to chart the future course of TB drug development.

Issue Release: 2011

Resistant TB: Newer Drugs and Community Approach.

Issue Release: 2011

Challenges and opportunities in developing novel drugs for TB.

Issue Release: 2011

TMC207: the first compound of a new class of potent anti-tuberculosis drugs.

Issue Release: 2010

[New horizons of next generation chemotherapy for mycobacteriosis].

Issue Release: 2009

Public-private partnership tackles TB challenges in parallel.

Issue Release: 2009

[Development of antituberculous drugs: current status and future prospects].

Issue Release: 2006

The global alliance for tuberculosis drug development--accomplishments and future directions.

Issue Release: 2005

Progress and new directions in genetics of tuberculosis: an NHLBI working group report.

Issue Release: 2005

Multidrug-resistant tuberculosis.

Issue Release: 2002

Giorgio Roscigno--senior advisor to the Global Alliance for TB Drug Development. Interviewed by Pam Das.

Issue Release: 2002

What Should Be Included in Patient Education Materials?

What is Regulatory Approval?

What Education and Training Do Pharmacists Need?

What Causes Adverse Drug Events?

How Can Pharmacists Contribute to Transitional Care?

Why Are Clinical Trials Important?

What is Pharmaceutical Science?

What is a New Drug Application (NDA)?

What are the Phases of Clinical Trials?

What are the Key Challenges?

Partnered Content Networks

Relevant Topics